Brain Cancer Therapeutics Market, by Indication (Glioblastoma, Meningioma, Pituitary Tumors, and Others), by Treatment Type (Targeted Therapy, Chemotherapy, Immunotherapy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Nov 2021

Code : CMI4769

Pages :190

Formats :

Excel and PDF

Industry : Pharmaceutical

Brain Cancer Therapeutics MarketSize and Trends

The global brain cancer therapeutics market is valued at US$ 2,539.0 million in 2021 and is expected to exhibit a CAGR of 9.8% during the forecast period (2021-2028).

An increase in the prevalence of brain cancer is expected to drive the global brain cancer therapeutics market growth over the forecast period. For instance, according to the American Association of Neurological Surgeons (AANS), a scientific and educational association, approximately 200,000 new cases of brain metastases are diagnosed in the U.S. each year, and the number is expected to be growing with increased awareness and improved diagnostic techniques.

Increasing morbidity of brain cancer is expected to drive the market growth during the forecast period.

Figure 1.Global Brain Cancer Therapeutics Market Share (%) in Terms of Value, by Indication, 2021

Increasing R&D spending for the development of new treatment methods and medical equipment is expected to drive the market growth during the forecast period.

Figure 2.Global Brain Cancer Therapeutics Market Share (%), by Distribution Channel, 2021

Market- Trends

Increasing R&D spending for the development of new treatment methods and medical equipment is expected to drive the market growth during the forecast period. For instance, according to a study published by 'Nature Medicine' in January 2020, a novel method that combines advanced optical imaging with an artificial intelligence algorithm was found to produce accurate and real-time intraoperative diagnosis of brain tumors in less than 3 minutes.